A Cardiff University graduate, Paul gained a first class degree in Biotechnology before completing a PhD in bacterial genetics. His early professional career was in big pharma, developing a high-throughput platform for screening genetic mutations that contribute to an individual’s response to therapeutics within GlaxoSmithKline’s Discovery Genetics department. In 2007 Paul joined Q Chip Ltd, where he was involved in the development of the company’s Q-Sphera technology for production of sustained-delivery therapeutics. In 2014 Q Chip was acquired by Midatech Pharma PLC and concurrently admitted to AIM, in an IPO raising £32m. As Head of Sustained Delivery, Paul is responsible for the development of Midatech Pharma’s Sustained Delivery product pipeline.